Kimberly Stegmaier

Kimberly Stegmaier

UNVERIFIED PROFILE

Are you Kimberly Stegmaier?   Register this Author

Register author
Kimberly Stegmaier

Kimberly Stegmaier

Publications by authors named "Kimberly Stegmaier"

Are you Kimberly Stegmaier?   Register this Author

84Publications

2400Reads

27Profile Views

Targeting chromatin complexes in fusion protein-driven malignancies.

Nat Rev Cancer 2019 05;19(5):255-269

Department of Pediatric Oncology, Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41568-019-0132-xDOI Listing
May 2019

Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias.

Cancer Cell 2019 Apr;35(4):664-676.e7

Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02445, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541931PMC
April 2019

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.

J Med Chem 2019 Mar 25;62(5):2428-2446. Epub 2019 Feb 25.

Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.8b01714DOI Listing
March 2019

Ushering in the next generation of precision trials for pediatric cancer.

Science 2019 Mar;363(6432):1175-1181

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aaw4153DOI Listing
March 2019

Targeted therapy for fusion-driven high-risk acute leukemia.

Blood 2018 09 26;132(12):1241-1247. Epub 2018 Jul 26.

Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-04-784157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148448PMC
September 2018

Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer.

Cell Rep 2018 Sep;24(13):3393-3403.e5

Department of Pediatric Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.08.089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365304PMC
September 2018

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.

Cancer Cell 2018 02 18;33(2):202-216.e6. Epub 2018 Jan 18.

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108173056
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2017.12.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846483PMC
February 2018

Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.

Bioorg Med Chem 2017 12 20;25(24):6479-6485. Epub 2017 Oct 20.

Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09680896173139
Publisher Site
http://dx.doi.org/10.1016/j.bmc.2017.10.025DOI Listing
December 2017

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

Cancer Cell 2017 09;32(3):271-273

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA; Broad Institute, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.08.011DOI Listing
September 2017

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.

Cancer Cell 2017 04;31(4):549-562.e11

Department of Medicine II, Hematology/Oncology, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; Department of Haematology, University of Cambridge, Hills Road, Cambridge CB2 0XY, UK; Cambridge Institute for Medical Research, Wellcome Trust/MRC Stem Cell Institute, Cambridge CB2 0XY, UK; German Cancer Research Center and German Cancer Consortium, 69120 Heidelberg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389883PMC
April 2017

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.

Cancer Discov 2016 08 3;6(8):914-29. Epub 2016 Jun 3.

Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972686PMC
August 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 07 11;30(1):183. Epub 2016 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.008DOI Listing
July 2016

Targeting MTHFD2 in acute myeloid leukemia.

J Exp Med 2016 06 20;213(7):1285-306. Epub 2016 Jun 20.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215 Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215 Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20151574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925018PMC
June 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 04;29(4):574-586

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991PMC
April 2016

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci Data 2014 30;1:140035. Epub 2014 Sep 30.

Broad Institute of Harvard and MIT, 7 Cambridge Center , Cambridge, Massachusetts 02142, USA ; Department of Medical, Dana-Farber Cancer Institute , 450 Brookline Avenue, Boston, Massachusetts 02215, USA ; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute , 450 Brookline Avenue, Boston, Massachusetts 02215, USA ; Departments of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/sdata201435
Publisher Site
http://dx.doi.org/10.1038/sdata.2014.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432652PMC
February 2016

Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia.

J Med Chem 2015 Nov 5;58(22):8907-19. Epub 2015 Nov 5.

Clemens Schöpf Institute of Organic Chemistry and Biochemistry, Technische Universität Darmstadt , 64287 Darmstadt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.5b01200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883112PMC
November 2015

New Approaches to Target T-ALL.

Front Oncol 2014 8;4:170. Epub 2014 Jul 8.

Department of Pediatric Oncology, Dana-Farber Cancer Institute , Boston, MA , USA ; Division of Hematology/Oncology, Boston Children's Hospital , Boston, MA , USA ; Broad Institute of Harvard and Massachusetts Institute of Technology , Cambridge, MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085879PMC
July 2014

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.

Nat Genet 2014 Apr 2;46(4):364-70. Epub 2014 Mar 2.

1] Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. [2] Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. [3] Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts, USA. [4] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ng.2913
Publisher Site
http://dx.doi.org/10.1038/ng.2913DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086945PMC
April 2014

Targeting Csnk1a1 in leukemia.

J Exp Med 2014 Apr;211(4):594

Dana-Farber Cancer Institute and Boston Children's Hospital.

View Article

Download full-text PDF

Source
http://www.jem.org/lookup/doi/10.1084/jem.2114insight1
Publisher Site
http://dx.doi.org/10.1084/jem.2114insight1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978273PMC
April 2014

SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Cancer Cell 2014 Feb;25(2):226-42

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA; The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.01.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106711PMC
February 2014

High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.

Cancer Res 2013 May 27;73(9):2873-83. Epub 2013 Mar 27.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-1944DOI Listing
May 2013

Targeting NOTCH1 in hematopoietic malignancy.

Crit Rev Oncog 2011 ;16(1-2):103-15

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
February 2012

Chemical genomics and combo therapy.

Blood 2010 Dec;116(26):5786-8

Dana-Farber Cancer Institute, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-10-312108DOI Listing
December 2010

Identification of AML1-ETO modulators by chemical genomics.

Blood 2009 Jun 17;113(24):6193-205. Epub 2009 Apr 17.

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-07-166090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699238PMC
June 2009

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

Proc Natl Acad Sci U S A 2008 Jul 7;105(28):9751-6. Epub 2008 Jul 7.

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0710413105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2474517PMC
July 2008

A method for high-throughput gene expression signature analysis.

Genome Biol 2006 ;7(7):R61

Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/gb-2006-7-7-r61DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779561PMC
May 2007

Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.

PLoS Med 2007 Apr;4(4):e122

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pmed.0040122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851624PMC
April 2007

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Cancer Cell 2006 Oct 28;10(4):321-30. Epub 2006 Sep 28.

The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2006.09.005DOI Listing
October 2006

Genomic approaches in acute leukemia.

Best Pract Res Clin Haematol 2006 ;19(2):263-8

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2005.11.001DOI Listing
July 2006

Gefitinib induces myeloid differentiation of acute myeloid leukemia.

Blood 2005 Oct 5;106(8):2841-8. Epub 2005 Jul 5.

D640/Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-02-0488DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895296PMC
October 2005

Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.

Nat Genet 2004 Mar 8;36(3):257-63. Epub 2004 Feb 8.

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng1305DOI Listing
March 2004